DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma

// Min Shi 1, * , Xiao-Yu Zhang 2, * , Heguo Yu 3 , Shi-Hao Xiang 1 , Ling Xu 1 , Jue Wei 1 , Qiong Wu 1 , Rongrong Jia 1 , Yu-Gang Wang 1 and Xiao-Jie Lu 4 1 Department of Gastroenterology, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China 2 Department of General Surgery, Division of Gastrointestinal Surgery, The Affiliated Huai’an Hospital of Xuzhou Medical College and The Second People’s Hospital of Huai’an, Huai’an, Jiangsu, China 3 NPFPC Key Laboratory of Contraceptives and Devices, Shanghai Institute of Planned Parenthood Research (SIPPR), Institutes of Reproduction and Development, Fudan University, Shanghai, China 4 Department of General Surgery, Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China * Co-first authors Correspondence to: Yu-Gang Wang, email: wangyugang2016@163.com Xiao-Jie Lu, email: 189@whu.edu.cn Keywords: liver hepatocellular carcinoma, lncRNAs, DDX11-AS1 Received: February 13, 2017      Accepted: March 24, 2017      Published: April 25, 2017 ABSTRACT Hepatocellular Carcinoma (HCC) is one of the most fatal cancers, whose incidence and death rates are still rising. Here, we report the identification of long non-coding RNAs (IncRNAs) that associated with HCC progression and metabolism based on the systematically analysis of large scale RNA-seq data from HCC patients. We identified seven lncRNAs with high confidence which were highly related with prognostic of HCC. Of note, three of them had quite different expression patterns between the control samples and the patients, and their critical roles in cancer progression were validated. We proposed that DDX11-AS1 play important role during HCC oncogenesis and may serve as potential therapy target for HCC.